A- A A+

Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts. 

Daiwile AP, Jayanthi S, Cadet JL. 

Neurosci Biobehav Rev. 2022 Jun;137:104674. doi: 10.1016/j.neubiorev.2022.104674. Epub 2022 Apr 20. PMID: 35452744; PMCID: PMC9119944.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119944/

Trends in Methamphetamine Use in the Mainland of China, 2006-2015.

Zhang B, Yan X, Li Y, Zhu H, Lu Z, Jia Z.

Front Public Health. 2022 Apr 28;10:852837. doi: 10.3389/fpubh.2022.852837. PMID: 35570894; PMCID: PMC9096246.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096246/

Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study. 

Corser J, Palis H, Fleury M, Lamb J, Lock K, McDougall J, Mehta A, Newman C, Spence H, Buxton JA. 

Harm Reduct J. 2022 May 19;19(1):46. doi: 10.1186/s12954-022-00630-8. PMID: 35590375; PMCID: PMC9118627.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118627/

How dangerous is MDMA? 

Frost J. 

Tidsskr Nor Laegeforen. 2022 May 19;142(8). English, Norwegian. doi: 10.4045/tidsskr.22.0309. PMID: 35635415.

https://tidsskriftet.no/en/2022/05/editorial/how-dangerous-mdma

Signals of increasing co-use of stimulants and opioids from online drug forum data. 

Sarker A, Al-Garadi MA, Ge Y, Nataraj N, Jones CM, Sumner SA. 

Harm Reduct J. 2022 May 25;19(1):51. doi: 10.1186/s12954-022-00628-2. PMID: 35614501; PMCID: PMC9131693.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131693/

UNODC. Synthetic Drugs in East and Southeast Asia Latest developments and challenges - 2022

United Nations Office on Drugs and Crime (UNODC), Global SMART Programme, 2022

https://www.unodc.org/roseap/uploads/documents/Publications/2022/Synthetic_Drugs_in_East_and_Southeast_Asia_2022_web.pdf

Patterns of and Rationale for the Co-use of Methamphetamine and Opioids: Findings From Qualitative Interviews in New Mexico and Nevada. 

Rhed BD, Harding RW, Marks C, Wagner KT, Fiuty P, Page K, Wagner KD. 

Front Psychiatry. 2022 Mar 28;13:824940. doi: 10.3389/fpsyt.2022.824940. PMID: 35418887; PMCID: PMC8995976.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995976/

Different phases of ATS use call for different interventions: a large qualitative study in Europe. 

Liebregts, N., Rigoni, R., Petruželka, B. et al.

Harm Reduct J 19, 36 (2022). doi.org/10.1186/s12954-022-00617-5

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00617-5

An adaptive design to screen, treat, and retain people with opioid use disorders who use methamphetamine in methadone clinics (STAR-OM): study protocol of a clinical trial. 

Giang LM, Trang NT, Diep NB, Thuy DTD, Thuy DT, Hoe HD, Van HTH, Truc TT, Nguyen HH, Lai NL, Linh PTD, Vi VTT, Reback CJ, Leibowitz A, Li L, Lin C, Li M, Do Van Dung, Shoptaw S. 

Trials. 2022 Apr 23;23(1):342. doi: 10.1186/s13063-022-06278-w. PMID: 35461300; PMCID: PMC9034071.

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06278-w

The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. 

Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, Emerson A, Brown RT, Doblin R. 

Drug Alcohol Depend. 2022 Apr 1;233:109356. doi: 10.1016/j.drugalcdep.2022.109356. Epub 2022 Feb 11. PMID: 35286849.

https://www.sciencedirect.com/science/article/pii/S037687162200093X?via%3Dihub

Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. 

Marseille E, Mitchell JM, Kahn JG (2022) 

PLoS ONE 17(2): e0263252. doi.org/10.1371/journal.pone.0263252

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263252

Current Situation of Methamphetamine Abuse and Related Research Progress. 

Hong SJ, Shen BY, Sun RJ, Yang GM, Duan CM, Nie QY, Zhang CB, Dong WJ, Yu H, Wang S, Liu PL, Wen PY, Li LH. 

Fa Yi Xue Za Zhi. 2021 Dec 25;37(6):763-775. English, Chinese. doi: 10.12116/j.issn.1004-5619.2021.310202. PMID: 35243841.

http://www.fyxzz.cn/CN/10.12116/j.issn.1004-5619.2021.310202

Oxytocin, a Novel Treatment for Methamphetamine Use Disorder. 

Edinoff AN, Thompson E, Merriman CE, Alvarez MR, Alpaugh ES, Cornett EM, Murnane KS, Kozinn RL, Shah-Bruce M, Kaye AM, Kaye AD. 

Neurol Int. 2022 Jan 30;14(1):186-198. doi: 10.3390/neurolint14010015. PMID: 35225885; PMCID: PMC8883935.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883935/

Shifting Pathways of Stimulant Use Among Individuals With Opioid Use Disorder: A Retrospective Analysis of the Last Thirty Years. 

Ellis MS, Kasper ZA, Scroggins S. 

Front Psychiatry. 2021 Dec 20;12:786056. doi: 10.3389/fpsyt.2021.786056. PMID: 34987431; PMCID: PMC8721201.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721201/

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada. 

Morin KA, Vojtesek F, Acharya S, Marsh DC. 

Front Psychiatry. 2021 Dec 20;12:782066. doi: 10.3389/fpsyt.2021.782066. PMID: 34987430; PMCID: PMC8721960.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721960/

Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor. 

Smith MA, Ballard SL, Ballesteros CF, Bonge SA, Casimir AT, Childs LM, Feinstein MA, Griffith AK, Johansen AN, Lee D, Mauser AC, Moses CM, Robertson IJ, Robles JU, Strickland JC, Walters ME, Yoo SJ. 

Front Psychiatry. 2022 Jan 5;12:790471. doi: 10.3389/fpsyt.2021.790471. PMID: 35069292; PMCID: PMC8766790.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766790/

Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. 

Ponte L, Jerome L, Hamilton S, Mithoefer MC, Yazar-Klosinski BB, Vermetten E, Feduccia AA. 

J Trauma Stress. 2021 Aug;34(4):851-863. doi: 10.1002/jts.22696. Epub 2021 Jun 10. PMID: 34114250; PMCID: PMC8453707.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453707/

Lay knowledge and practices of methamphetamine use to manage opioid-related overdose risks. 

Daniulaityte R, Silverstein SM, Getz K, Juhascik M, McElhinny M, Dudley S. 

Int J Drug Policy. 2021 Oct 4;99:103463. doi: 10.1016/j.drugpo.2021.103463. Epub ahead of print. PMID: 34619443.

https://www.sciencedirect.com/science/article/pii/S0955395921003686

The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. 

Frost MC, Lampert H, Tsui JI, Iles-Shih MD, Williams EC. 

Addict Sci Clin Pract. 2021 Oct 11;16(1):62. doi: 10.1186/s13722-021-00266-2. PMID: 34635170; PMCID: PMC8504567.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504567/

Methamphetamine use and HIV risk behavior among men who inject drugs: causal inference using coarsened exact matching. 

Noroozi M, Higgs P, Noroozi A, Armoon B, Mousavi B, Alikhani R, Bazrafshan MR, Astaneh AN, Bayani A, Moghaddam LF. 

Harm Reduct J. 2020 Sep 21;17(1):66. doi: 10.1186/s12954-020-00411-1. PMID: 32957982; PMCID: PMC7507738.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507738/

SAMHSA. Treatment Improvement Protocol (TIP) 33: Treatment for Stimulant Use Disorders

This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, 2021)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-004.pdf

The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. 

Grimmsmann T, Himmel W. 

Eur J Clin Pharmacol. 2021 Jan;77(1):107-115. doi: 10.1007/s00228-020-02948-3. Epub 2020 Aug 17. PMID: 32803292; PMCID: PMC7782395.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782395/

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment. 

Palis H, Marchand K, Peachey GS, Westfall J, Lock K, MacDonald S, Jun J, Bojanczyk-Shibata A, Harrison S, Marsh DC, Schechter MT, Oviedo-Joekes E. 

Subst Abuse Treat Prev Policy. 2021 Sep 16;16(1):68. doi: 10.1186/s13011-021-00399-2. PMID: 34530878; PMCID: PMC8444161.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444161/

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. 

Siffel C, Page M, Maxwell T, Thun B, Kolb N, Rosenlund M, von Bredow D, Keja J. 

J Child Adolesc Psychopharmacol. 2020 Sep;30(7):439-447. doi: 10.1089/cap.2019.0173. Epub 2020 Apr 21. PMID: 32315539; PMCID: PMC7475084.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475084/

Benzodiazepines and Amphetamines Use among Methadone Maintenance Participants and Their Associations with Treatment Adherence. 

Cheng Z, Diao F, Chen GH, Lin CQ, Li L, Wu ZY, Cao XB.

Biomed Environ Sci. 2021 Jun 20;34(6):499-502. doi: 10.3967/bes2021.069. PMID: 34284859.

http://www.besjournal.com/en/article/doi/10.3967/bes2021.069

Methamphetamine Use and Its Correlates among Individuals with Opioid Use Disorder in a Midwestern U.S. City. 

Daniulaityte R, Silverstein SM, Crawford TN, Martins SS, Zule W, Zaragoza AJ, Carlson RG. 

Subst Use Misuse. 2020;55(11):1781-1789. doi: 10.1080/10826084.2020.1765805. Epub 2020 May 22. PMID: 32441178; PMCID: PMC7473491.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473491/

The Abuse Characteristics of Amphetamine-Type Stimulants in Patients Receiving Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment. 

Liu Y, Liu N, Shen W, Li L, Zhou W, Xu L. 

Drug Des Devel Ther. 2021 May 18;15:2109-2116. doi: 10.2147/DDDT.S305226. PMID: 34040349; PMCID: PMC8140901.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140901/

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report. 

Palis, H., MacDonald, S., Jun, J. et al. 

Harm Reduct J 18, 57 (2021). doi.org/10.1186/s12954-021-00500-9

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00500-9

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. 

Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. 

Nat Med (2021). doi.org/10.1038/s41591-021-01336-3

https://www.nature.com/articles/s41591-021-01336-3

Fatal and non-fatal health incidents related to recreational ecstasy use. 

van Amsterdam J, Pennings E, van den Brink W. 

J Psychopharmacol. 2020 Jun;34(6):591-599. doi: 10.1177/0269881119897559. Epub 2020 Jan 7. PMID: 31909673; PMCID: PMC7249611.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249611/